We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
Cap. Flow
-$118M
Cap. Flow %
-3.94%
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$40.3M
2
ARGX icon
argenx
ARGX
+$39.9M
3
RVMD icon
Revolution Medicines
RVMD
+$39.2M
4
IMVT icon
Immunovant
IMVT
+$29.2M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$16.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.3M
2
VIR icon
Vir Biotechnology
VIR
+$48M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$46.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$35.7M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLGC
76
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.58M 0.12%
1,500,000
– –
TVTX icon
77
Travere Therapeutics
TVTX
$6.32B
$3.58M 0.12%
400,000
+309,252
+341% +$4.36M
SRPT icon
78
CALL
Sarepta Therapeutics
SRPT
$2B
$3.13M 0.1%
+100,000
New +$11.3M
PNT
79
PUT
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$2.63M 0.09%
800,000
+300,000
+60% +$2.49M
ARQT icon
80
PUT
Arcutis Biotherapeutics
ARQT
$3.12B
$2.62M 0.09%
300,000
– –
EYPT icon
81
PUT
EyePoint Inc
EYPT
$431M
$2.51M 0.08%
+750,000
New +$8.22M
KRON
82
DELISTED
Kronos Bio
KRON
$2.28M 0.08%
1,752,745
– –
FBRX icon
83
Forte Biosciences
FBRX
$1.63B
$2.16M 0.07%
+130,614
New +$2.9M
SLRN
84
DELISTED
ACELYRIN
SLRN
$2.03M 0.07%
200,000
– –
ETNB
85
CALL
DELISTED
89bio
ETNB
$1.62M 0.05%
+400,000
New +$6.71M
ACRS icon
86
PUT
Aclaris Therapeutics
ACRS
$963M
$1.45M 0.05%
+500,000
New +$4.27M
SYRE icon
87
Spyre Therapeutics
SYRE
$9.47B
$994K 0.03%
+81,116
New +$1.07M
VBIV
88
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$926K 0.03%
1,381,355
– –
OMIC
89
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$900K 0.03%
78,774
– –
VERU icon
90
Veru
VERU
$46.2M
$784K 0.03%
108,988
+100,000
+1,113% +$1.09M
VKTX icon
91
CALL
Viking Therapeutics
VKTX
$3.99B
$240K 0.01%
+300,000
New +$4.29M
APLS
92
PUT
DELISTED
Apellis Pharmaceuticals
APLS
$72.5K ﹤0.01%
+100,000
New +$4.39M
CYPH
93
Cypherpunk Technologies Inc
CYPH
$177M
$62.1K ﹤0.01%
44,971
-541,762
-92% -$1.26M
MOTS
94
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$40.5K ﹤0.01%
6,002
– –
CMAXW
95
DELISTED
CareMax, Inc. Warrant
CMAXW
$11.3K ﹤0.01%
60,000
– –
EQRXW
96
DELISTED
EQRx, Inc. Warrant
EQRXW
$10K ﹤0.01%
250,000
– –
SRZNW
97
DELISTED
Surrozen Inc Warrant
SRZNW
$6.67K ﹤0.01%
166,666
– –
APLS
98
DELISTED
Apellis Pharmaceuticals
APLS
– –
-812,037
Closed -$35.7M
BMRN icon
99
BioMarin Pharmaceuticals
BMRN
$12.8B
– –
-263,207
Closed -$22.8M
BTAI icon
100
CALL
BioXcel Therapeutics
BTAI
$23.2M
– –
-27,469
Closed -$11K
1 2 3
4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $118M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.

  • Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
  • Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
  • Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
  • Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
  • Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
  • Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.